Mar

7

BioCurex Inc. (Symbol: BOCX)

Filed Under Biotechnology & Drugs 

There are over 8 million cancer patients in North America, with approximately 1 million more people developing cancer each year. Over one third of the population will develop cancer at some point during their life and over one-half a million people die from cancer each year. The new incidences of cancer, along with the maintenance of persons living with cancer continue to increase the demand for cancer products on a large scale.

The present world market for cancer therapeutics alone is approximately US$ 6.5 billion with an expected increase towards US$15 billion by the year 2002. The National Cancer Institute estimates the overall annual costs for cancer in the U.S. at US$104 billion with US$35 billion in direct medical costs and the remainder in productivity and mortality-related costs. Approximately one half of the direct costs are related to the treatment of breast, lung and prostate cancers. On a global basis, costs associated with cancer related illnesses are estimated at more than $150 billion. This is where BioCurex Inc. (Symbol: BOCX) enters the market.

BioCurex Inc. is currently developing these following products:

HISTOLOGY AND CYTOLOGY BioCurex’s Histo-RECAF™ is a special cancer detection kit for tissues that stains cancer cells brown, clearly distinguishing them from normal healthy cells. Pathologists are able to easily identify cancer cells under a conventional microscope for making a diagnosis.

LEUKEMIA Using our technology, leukemia cells can be “lit up” so that only infected blood cancer cells are isolated for targeted treatment. The clear implication of the BioCurex technology is that physicians can detect any recurrence of the blood cancer at a very early stage using equipment that is available today.

BLOOD AND SERUM TESTS Using our technology, a basic blood test can determine if a patient has cancer. Cancer cells shed our cancer marker RECAF™ into the blood stream where it is detected. Because of its powerful detection capability and simple execution, the Serum-RECAF™ will be a standardized blood test widely available in any clinical laboratory. Physicians can then use Serum-RECAF™ as frequently as required for both the initial screening of patients with symptoms, and monitoring of those patients who have been previously treated for cancer.

TUMOR IMAGING Once cancer has been diagnosed, it is crucial to determine its location and size. Because the RECAF™ technology effectively detects cancer cells, cancer tissue can be targeted with special compounds administered to the patient. Since only cancer cells are selected, tumor locations can then be imaged using standard equipment.Recently they announced that Dr. Steward Sell has joined the Scientific Advisory Board of BioCurex Inc. Dr. Steward Sell is an internationally renowned physician and scientist in the cancer and stem cell fields. In addition to obtaining his medical degree at the University of Pittsburgh, his residency in Pathology at Massachusetts General Hospital, and research in Immunology at National Institute of Health, Bethesda and University of Birmingham, he has also received many awards including the Virchow Award (in honor of the recognized father of pathology), Legacy Laureate of the University of Pittsburgh, (which recognizes the University’s most distinguished graduates), Distinguished Scientist by the International Academy of Tumor Marker Oncology, the Gary Miller Memorial Award from the American Association for Cancer Research (AACR) and recently, a special award from the AACR for his contributions to teaching principles of cancer biology over the last 25 years. Yupp, that’s a pretty distinguished resume, if I might add :)

Below is their stock performance for the past 6 months.

Source: http://biocurex.com

Quote of the Day:
The stocks I try to buy are the very stocks that traditional fund managers try to overlook. In other words, I continue to think like an amateur as frequently as possible. – Peter Lynch

  • Share/Bookmark

Comments

One Response to “BioCurex Inc. (Symbol: BOCX)”

  1. Colonel on July 3rd, 2011 8:46 am

    Furrealz? That’s mvareolsuly good to know.

Leave a Reply